| Wrongfully accused: metformin use in heart failure. | |
| | |
MedLine Citation:
|
PMID: 21453211 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Evaluation of: Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail. 4(1), 53-58 (2010). Metformin has long been the cornerstone of therapy for glycemic control in patients with Type 2 diabetes worldwide. It is recommended as first-line therapy by all major diabetes clinical practice guidelines owing to its efficacy, favorable tolerability profile and beneficial effects in limiting weight gain. Moreover, metformin is the only oral anthyperglycemic agent shown in randomized controlled trials to reduce mortality in newly diagnosed patients with Type 2 diabetes. However, the use of metformin has not been without controversy, in particular in patients with heart failure. This article will review a recent observational study by Aguilar et al. published in Circulation - Heart Failure that reported improved outcomes associated with metformin therapy in patients with diabetes and heart failure. |
| | |
Authors:
|
Dean T Eurich; Finlay A McAlister |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 9 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-04-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 147-50 Citation Subset: IM |
Affiliation:
|
School of Public Health, University of Alberta, Edmonton, AL, T6G 2T4, Canada. deurich@ualberta.ca. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lipid-lowering effects of ezetimibe and simvastatin in combination.
Next Document: The rise of hemodialysis machines: new technologies in minimizing cardiovascular complications.